TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00940563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Study: NCT00064038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02609893

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing-based counseling
Description: Motivational Interviewing-based risk reduction and medication adherence counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing-based counseling
Description: Motivational Interviewing-based risk reduction and medication adherence counseling
Study: NCT01359982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: Dose level 1 (10 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: Dose Level 2 (16.7 mg/m2)
Study: NCT00394303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative continuous insulin infusion
Description: Nomogram specified in appendix

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: Glucose management according to the discretion of the anesthesiologist aimed to maintain glucose levels \<200 mg.dl, reflecting current practice.
Study: NCT02798458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartpill
Description: The SmartPill Test is approved by the U.S. Food and Drug Administration (FDA) to measure transit time in the GI tract. This procedure uses the SmartPill capsule, a receiver, and computer software.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartpill
Description: The SmartPill Test is approved by the U.S. Food and Drug Administration (FDA) to measure transit time in the GI tract. This procedure uses the SmartPill capsule, a receiver, and computer software.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection
Description: a Sigmoidoscopy is an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed.
Study: NCT04336605

Intervention type: OTHER
Intervention: Age & Development
Description: Age, sex, pubertal onset and development

Intervention type: OTHER
Intervention: Socioeconomy
Description: Family structure and economy

Intervention type: OTHER
Intervention: Traumatic Events
Description: Violence and other traumatic events

Intervention type: OTHER
Intervention: Psychosocial conditions
Description: Family/social support

Intervention type: OTHER
Intervention: Lifestyle
Description: Physical activity, BMI, nutrition, smoking ...

Intervention type: OTHER
Intervention: Chronic conditions
Description: I.e. Epilepsy or juvenile rheumatoid arthritis ...

Intervention type: OTHER
Intervention: Somatic symptoms
Description: Headache, pain, sleep disturbances ...

Intervention type: OTHER
Intervention: Psychological symptoms
Description: PTSS, anxiety, depressive symptoms \& loneliness ...
Study: NCT04336605

Intervention type: OTHER
Intervention: Non-prescription analgesics
Description: Non-prescription analgesics

Intervention type: OTHER
Intervention: Prescription drugs
Description: Analgetic, sedative \& anxiolytic medication
Study: NCT03545022

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The application of acupuncture was performed in four sessions, 30 minutes prior to surgery, 24, 48 and 72 hours following the surgery, before variables measurements. The points were manually stimulated and the needles were inserted up to 4mm. There were 11 points, applied bilaterally, two of them, point VG20 and Yintang, for anxiety control, only at the preoperative time and not bilateral. The points to reduce pain, edema, and trismus were IG4 (Hegu), F3 (Taichong) and E44 (Neiting), TA21 (Ermen), ID19 (Ting-Kong), E6 (Jiagle) and E7 (Towei) , point B60 (Kunlum) and VB34 (Yanglingquan). All patients received the same treatment in all sessions.~After the needle devices were inserted, the needles were re-stimulated manually once after 10 minutes and removed after more 10 minutes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: The application of acupuncture was performed in four sessions, 30 minutes prior to surgery, 24, 48 and 72 hours following the surgery, before variables measurements. The points were manually stimulated and the needles were inserted up to 4mm. There were 11 points, applied bilaterally, two of them, point VG20 and Yintang, for anxiety control, only at the preoperative time and not bilateral. The points to reduce pain, edema, and trismus were IG4 (Hegu), F3 (Taichong) and E44 (Neiting), TA21 (Ermen), ID19 (Ting-Kong), E6 (Jiagle) and E7 (Towei) , point B60 (Kunlum) and VB34 (Yanglingquan). All patients received the same treatment in all sessions.~After the needle devices were inserted, the needles were re-stimulated manually once after 10 minutes and removed after more 10 minutes.
Study: NCT00834873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg tablets
Description: 1 x 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COREG® 25 mg tablets
Description: 1 x 25 mg
Study: NCT01977521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eldith DC Stimulator stimulation
Description: The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation will consist of 2 mA for 20 minutes per session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Eldith DC Stimulator sham stimulation
Description: The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). In the sham condition, after 40 seconds of real stimulation (2 mA), only a small current pulse will occur every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
Study: NCT00907387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RT001
Description: Dose A RT001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RT001
Description: Dose B RT001

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose C Placebo
Study: NCT04722198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS128
Description: daily ingestion 2 capsules of Lactobacillus plantarum PS128 (\>10 billion CFU/capsule)
Study: NCT03577938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Description: One dosage of CHM includes Artemisiacapillaris Thunb (30g), Salvia miltiorrhiza Bge (30g), Rhizoma Atractylodis Macroce- phalae (30g), Rubia cordifolia L (30g), Sieyesbeckiaorientalis L (30g). Paeoniae Radix Rubra (60g), Gardenia jasminoides Ellis (9g), Hedyotis diffusa Willd (30g) and Bletilla striata (15g) are involved for excess syndrome, and Astragalus membranaceus (30g), Radix Pseudostellariae (15g), Radix Aconiti Lateralis Praeparata (10g), Galli Gigeriae Endothelium Corneum (20g), Polygonum cuspidatum Sieb.et Zucc (15g) are involved for deficiency syndrome.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (blank)
Description: SMT therapy includes a high-calorie diet; nucleoside analogues for HBV DNA-positive patients; sodium restriction, diuretics and paracentesis combined with albumin infusion for ascites; lactulose and L-ornithine aspartate and lactulose for HE and hyper-ammonia; hemostatic treatment for gastrointestinal hemorrhage; antibiotics for infections and renal replacement for HRS and uremic symptoms.

Intervention type: OTHER
Group type: OTHER
Intervention: Control (blank)
Description: SMT therapy includes a high-calorie diet; nucleoside analogues for HBV DNA-positive patients; sodium restriction, diuretics and paracentesis combined with albumin infusion for ascites; lactulose and L-ornithine aspartate and lactulose for HE and hyper-ammonia; hemostatic treatment for gastrointestinal hemorrhage; antibiotics for infections and renal replacement for HRS and uremic symptoms.
Study: NCT02440607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cognitive Aid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Cognitive Aid
Study: NCT01334242

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Schedule A
Description: Dosing 1 hour before breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Schedule B
Description: Dosing 0.5 hour before breakfast
Study: NCT00598052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: 10mg/day
Study: NCT02985281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: antiviral drug for HCV infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: antiviral drug for HCV infection
Study: NCT01829165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS Treatment
Description: MRI-compatible TMS stimulator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS Treatment
Study: NCT03055221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Treprostinil
Description: Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
Study: NCT03410537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04461535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone
Description: Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.
Study: NCT01881295

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose potassium gluconate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium dose potassium gluconate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose potassium gluconate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose potato

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium dose potato

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose potato

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose French fries

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Basal diet control
Study: NCT02164721

Intervention type: DEVICE
Group type: OTHER
Intervention: Three-lead CRT-D (Defibrillator)
Description: The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
Study: NCT01567020

Intervention type: OTHER
Intervention: Diagnostic
Description: All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.

Intervention type: OTHER
Intervention: Diagnostic
Description: All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.

Intervention type: OTHER
Intervention: Diagnostic
Description: All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.

Intervention type: OTHER
Intervention: Diagnostic
Description: All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.
Study: NCT04267328

Intervention type: PROCEDURE
Intervention: Elective Orthopedic Surgery
Description: Patients having knee (unilateral primary osteoarthritis or bilateral primary osteoarthritis) surgery, hip (unilateral primary osteoarthritis or bilateral primary osteoarthritis) or shoulder (primary osteoarthritis) elective surgery.
Study: NCT04619030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality
Description: The patient leaflet has an Augmented Reality model that appears out of the leaflet when viewed with a smartphone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional leaflet
Description: Traditional leaflet with no Augmented Reality capability
Study: NCT03843970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Hydrochloride 0.5%
Description: The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isobaric bupivacaine 0.5%
Description: The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.
Study: NCT02329275

Intervention type: PROCEDURE
Intervention: Testicular biopsy

Intervention type: PROCEDURE
Intervention: Testicular biopsy
Study: NCT03926598

Intervention type: BEHAVIORAL
Intervention: Patient and/or Family Member Intervention
Description: On the Patient Login Screen, log in using your last name and session ID provided by the research team on the Surveys Screen, click on a pending survey when the survey opens, respond to the survey submit the survey log out of the Guide-Goals Application.

Intervention type: BEHAVIORAL
Intervention: Certified Diabetes Educator Intervention
Description: On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.

Intervention type: BEHAVIORAL
Intervention: Physician Intervention
Description: On the Provider Login Screen, log in using the username and password provided by the research team on the Patient Screen, add a new patient on the Edit Patient Screen, add the Diabetes Family Responsibility Questionnaire on the Edit Patient Screen, create a survey access code to share with the patient.

Intervention type: BEHAVIORAL
Intervention: Front Desk Staff Intervention
Description: On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.

Intervention type: BEHAVIORAL
Intervention: Nurse Intervention
Description: On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status screen, change HbA1C value to 10% on the Visit Status screen, change Nephropathy evaluation to Abnormal log out of Guide to Goals application.
Study: NCT01359982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: Dose Level 3 (24.6 mg/m2)
Study: NCT03676725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Description: Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)
Study: NCT01972971

Intervention type: OTHER
Group type: OTHER
Intervention: patient education
Description: one by one patient education
Study: NCT00805220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic Walking
Description: Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
Study: NCT01030575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol lower volume
Description: 5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol mid-level volume
Description: 20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol high volume
Description: 40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo low volume
Description: Glucose 5% given in volumes equal to that of the comparator drug
Study: NCT02475057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix (LHRH antagonist)
Description: Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH agonist
Description: LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoPAT2000
Description: Peripheral arterial plethysmography using an EndoPAT2000 device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoPAT2000
Description: Peripheral arterial plethysmography using an EndoPAT2000 device
Study: NCT02520440

Intervention type: BIOLOGICAL
Intervention: Monitoring of plasmatic levels of Citrulline
Description: Measured plasma amino-acids levels

Intervention type: BIOLOGICAL
Intervention: Monitoring of plasmatic levels of Citrulline
Description: Measured plasma amino-acids levels

Intervention type: DEVICE
Intervention: Intra-abdominal pressure monitoring
Description: Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.

Intervention type: DEVICE
Intervention: Intra-abdominal pressure monitoring
Description: Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.

Intervention type: BIOLOGICAL
Intervention: Monitoring of plasmatic levels of Arginine and Glutamine
Description: Measured plasma amino-acids levels
Study: NCT01359982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: Dose Level 4 (33 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: Dose Level 5 (55.0 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: Dose Level 6 (83 mg/m2)
Study: NCT04866836

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients who meet the criteria for enrollment first receive radiotherapy, either IMRT or SBRT, and the relative biological effect dose is\> 40Gy. On the 7th day (±3 days) after radiotherapy, start to give tislelizumab 200 mg, IVD, q3w, and continue the treatment until disease progression, unacceptable toxic radiotherapy, death or meet the description in the protocol Any discontinuation criteria shall be subject to whichever occurs firs
Study: NCT03291379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTG-002814
Description: BTG-002814 containing 100 mg vandetanib
Study: NCT02195648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital inhibition
Description: Experimental: Suboccipital inhibition~The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles.
Study: NCT01634347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol and memory reactivation
Description: Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and memory reactivation
Description: Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
Study: NCT03088150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal ablation
Description: Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection
Description: In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
Study: NCT03958201

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex
Description: The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
Study: NCT03335124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Intravenous thiamine will be applied as per instructions described in arm/group descriptions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: 0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.
Study: NCT03507400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Introvision: mental and emotional self-regulation
Description: Participants learn Introvision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Introvision: mental and emotional self-regulation
Description: Participants learn Introvision